UK sets up vac­cines cen­tre as Brex­it looms; Shang­hai's Elpi­science bags $35M in Se­ries B

→ Hill­house Cap­i­tal has joined Lil­ly Asia Ven­tures and CDH In­vest­ments in back­ing Elpi­science, lead­ing a $35 mil­lion Se­ries B to boost its can­cer im­munother­a­py pipeline. The Shang­hai-based biotech is gear­ing up IND fil­ing for two of its 12 as­sets, sev­er­al of which are in-li­censed from re­gion­al and glob­al in­sti­tu­tions.

→ With Brex­it threat­en­ing to dis­rupt the phar­ma­ceu­ti­cal sup­ply chain in the coun­try, and hav­ing lost the EMA head­quar­ters to Am­s­ter­dam, the UK is work­ing on ways to sal­vage its £70 bil­lion life sci­ences in­dus­try. Over the week­end, the gov­ern­ment an­nounced the first-ever vac­cines man­u­fac­tur­ing in­no­va­tion cen­tre to tack­le dead­ly dis­eases such as Ebo­la and Las­sa fever.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER